These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19185908)

  • 21. Improved prostate cancer treatment.
    Health News; 2002 Sep; 8(9):8. PubMed ID: 12229905
    [No Abstract]   [Full Text] [Related]  

  • 22. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
    Bellmunt J; Rosenberg JE; Choueiri TK
    Eur Urol; 2009 Oct; 56(4):606-8. PubMed ID: 19635642
    [No Abstract]   [Full Text] [Related]  

  • 24. Total androgen suppression in the management of prostatic cancer. A critical review.
    Schroeder FH
    Prog Clin Biol Res; 1985; 185A():307-17. PubMed ID: 3898133
    [No Abstract]   [Full Text] [Related]  

  • 25. [Principles for the conservative drug therapy treatment of prostate cancer].
    Hofmann W
    Z Urol Nephrol; 1981 Sep; 74(9):697-704. PubMed ID: 7314992
    [No Abstract]   [Full Text] [Related]  

  • 26. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    D'Amico AV
    J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901
    [No Abstract]   [Full Text] [Related]  

  • 27. [Proton hypophysectomy and subtotal body irradiation in combined treatment of stage IV prostate cancer].
    Aleksandrov VP; Kondrat'eva EA; Karelin MI; Konnov BA; Zharinov GM; Metelev VV; Pecherskiĭ AV
    Urologiia; 1999; (6):26-8. PubMed ID: 16859000
    [No Abstract]   [Full Text] [Related]  

  • 28. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cryoimmunology and prostatic cancer].
    Sesia G
    J Urol Nephrol (Paris); 1977; 83 Suppl 2():416-7. PubMed ID: 617704
    [No Abstract]   [Full Text] [Related]  

  • 30. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical castration and survival in low-risk prostate cancer.
    van der Poel HG
    Eur Urol; 2009 Oct; 56(4):617-8. PubMed ID: 19349109
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of castration-resistant prostate cancer: a call to urologists.
    Fitzpatrick JM
    BJU Int; 2012 Sep; 110(6):772-4. PubMed ID: 22882501
    [No Abstract]   [Full Text] [Related]  

  • 33. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 34. Choice of hormonal therapy for prostate cancer.
    Reese DM
    Lancet; 2000 Apr; 355(9214):1474-5. PubMed ID: 10801162
    [No Abstract]   [Full Text] [Related]  

  • 35. Hormonal therapy of prostatic cancer.
    Scott WW; Menon M; Walsh PC
    Cancer; 1980 Apr; 45(7 Suppl):1929-36. PubMed ID: 7370944
    [No Abstract]   [Full Text] [Related]  

  • 36. Faltin lecture 1988. Prostate cancer: current concepts on therapy.
    Andersson L
    Ann Chir Gynaecol; 1989; 78(2):88-93. PubMed ID: 2802498
    [No Abstract]   [Full Text] [Related]  

  • 37. Flutamide plus castration in patients with previously untreated prostate cancer.
    Labrie F
    Urology; 1997 Sep; 50(3):479. PubMed ID: 9301724
    [No Abstract]   [Full Text] [Related]  

  • 38. Reasons against total androgen suppression.
    Robinson MR
    Prog Clin Biol Res; 1990; 359():117-24; discussion 141-53. PubMed ID: 2284287
    [No Abstract]   [Full Text] [Related]  

  • 39. Castration-resistant prostate cancer: descriptive yet pejorative?
    Crawford ED; Petrylak D
    J Clin Oncol; 2010 Aug; 28(23):e408. PubMed ID: 20547989
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.
    Bamias A; Dimopoulos MA
    Eur Urol; 2008 May; 53(5):899-900. PubMed ID: 18201817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.